Welcome to our dedicated page for Chimerix SEC filings (Ticker: CMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing SEC documents loaded with clinical trial jargon, milestone payments and royalty clauses is tough—especially when Chimerix’s pipeline spans first-in-class imipridones and legacy antivirals. If you’ve ever searched for “Chimerix SEC filings explained simply” and still felt lost, this page solves that problem.
Stock Titan’s AI reads every 10-K annual report, 10-Q quarterly earnings report and 8-K material event the moment it hits EDGAR, then delivers plain-language highlights in seconds. Need “Chimerix quarterly earnings report 10-Q filing” numbers without wading through accounting footnotes? Curious about “Chimerix insider trading Form 4 transactions” minutes after an executive buys shares? Our real-time engine flags the data, summarizes why it matters and links back to the original PDF for deeper review.
- Form 4 insider transactions real-time – track “Chimerix executive stock transactions Form 4” to gauge management confidence ahead of Phase 3 readouts.
- 10-K simplified – see R&D spend, cash runway and royalty streams under the heading “Chimerix annual report 10-K simplified.”
- Proxy statement executive compensation – understand option grants tied to clinical milestones.
- 8-K material events explained – immediate alerts when the FDA grants Fast Track or when licensing revenue changes.
Whether you’re modeling dilution risk, monitoring “Chimerix earnings report filing analysis,” or simply understanding Chimerix SEC documents with AI, you’ll find every disclosure here—updated in real time, summarized with context and ready for comparison against sector peers.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed a Schedule 13G/A reporting that they beneficially own 0.00 shares of Chimerix common stock, representing 0.0% of the class. The cover pages show 0.00 sole and shared voting power and 0.00 sole and shared dispositive power, indicating no reportable economic or voting stake in the issuer as disclosed.
The filing includes a joint filing agreement and an exhibit identifying Goldman Sachs & Co. LLC as a subsidiary of The Goldman Sachs Group, Inc. It also states ownership is five percent or less and that the securities are held in the ordinary course of business and were not acquired to influence control.
FAQ
What is the current stock price of Chimerix (CMRX)?
What is the market cap of Chimerix (CMRX)?
